Skip to main content

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Therapeutic Areas
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.

Section Overview

Therapeutic Areas

Section Overview

Metabolic

Respiratory

Acute Ischemic Stroke
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

See all products

Products

See all products
Resources
Contact us
Logout

Boehringer Ingelheim

Full Prescribing Information Opens in new tab

Full Prescribing Information Opens in new tab

Home
Clinical Trials
Dosing
MOA
Resources
Advancing PF care

Resources

PC-IME-100592

PDF

OFEV®(nintedanib) is a Recommended Treatment Option at Diagnosis for SSc-ILD Patients If Pharmacological Treatment is Required

PC-IME-100592 (December 2026 )

Download Opens in new tab

PC-IME-100576

0:58

How to Suspect ILD

PC-IME-100576 (August 2026 )

Watch now Opens in new tab

Home
Respiratory
OFEV
Resources

Vault id: PC-IM-100562

Sitemap

Therapeutic Area

Resources
- Videos
- Clinical studies

Site Map
Privacy Policy
Terms & Conditions
Contact

BI-logo

.

© 2010-2026 Boehringer Ingelheim International GmbH. All rights reserved. PC-AE-101942